---
title: "Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688016.SH.md"
symbol: "688016.SH"
name: "Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd."
industry: "Health Care Supplies"
datetime: "2026-05-20T03:01:30.922Z"
locales:
  - [en](https://longbridge.com/en/quote/688016.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688016.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688016.SH.md)
---

# Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. (688016.SH)

## Company Overview

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low profile delivery system. It also provides Minos, an abdominal aortic stent graft and delivery System; Aorfix, an endovascular device designed for treating abdominal aortic aneurysms; Altura, a device designed for the endovascular repair of abdominal aortic aneurysms; Aegis, a bifurcated aortic stent graft system; and L-REBOA, an aortic occlusion balloon catheter.

| Item | Detail |
|------|--------|
| Industry | Health Care Supplies |
| Exchange | CN Market |
| Website | [www.endovastec.com](https://www.endovastec.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: B (0.31)**

**Industry**: Health Care Supplies

| Metric | Value |
|--------|-------|
| Industry Ranking | 5 / 40 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 17.64% |  |
| Net Profit YoY | 31.53% |  |
| P/B Ratio | 2.90 |  |
| Dividend Ratio | 1.63% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 12203611264.20 |  |
| Revenue | 1387353388.38 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 14.60% | B |
| Profit Margin | 42.38% | A |
| Gross Margin | 73.13% | A |
| Revenue YoY | 17.64% | B |
| Net Profit YoY | 31.53% | B |
| Total Assets YoY | 7.37% | B |
| Net Assets YoY | 9.13% | B |
| Cash Flow Margin | 92.39% | C |
| OCF YoY | 17.64% | B |
| Turnover | 0.30 | D |
| Gearing Ratio | 11.57% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "17.64%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "31.53%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.90",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.63%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "12203611264.20",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1387353388.38",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "14.60%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "42.38%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "73.13%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "17.64%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "31.53%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "7.37%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.13%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "92.39%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "17.64%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.30",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "11.57%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 20.81 | 5/40 | 32.85 | 30.90 | 24.23 |
| PB | 2.90 | 27/40 | 3.35 | 3.07 | 2.90 |
| PS (TTM) | 8.82 | 30/40 | 11.54 | 9.67 | 9.14 |
| Dividend Yield | 1.63% | 15/40 | 1.91% | 1.75% | 1.62% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Snibe (300832.SZ) | A | D | C | A | C | B |
| 02 | Winner Medical (300888.SZ) | B | B | B | B | B | B |
| 03 | Fuerjia (301371.SZ) | B | C | D | A | B | B |
| 04 | MTM (688029.SH) | B | B | B | A | B | B |
| 05 | Endovastec (688016.SH) | A | B | D | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T16:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 71% |
| Overweight | 1 | 14% |
| Hold | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 97.76 |
| Highest Target | 150.00 |
| Lowest Target | 94.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688016.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688016.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688016.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688016.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**